← Leaderboards
Jaipal Singh
Vasculonics, Llc
$3,638,335
Attributed
$3,638,335
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.3M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,638,335 · 4
By mechanism
R44$2,354,098 · 1
R33$831,753 · 1
R43$452,484 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Mortality”
- Chanza Baytop · Westat, Inc.$271,217,917
- Beth Baseler · Leidos Biomedical Research, Inc.$87,027,148
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$56,084,949
- Greg Witham · Anp Technologies, Inc.$19,727,817
- Yunda Huang · Fred Hutchinson Cancer Center$19,033,873
- Barbara Halina Braffett · George Washington University$17,931,151
Research focus
MortalityFibrosisSafety StudyPathologicPre-Clinical ModelDimethylargininaseLeadRattusInflammationPathway InteractionsTargeted TreatmentBlood VesselsClinical CandidateDrug KineticsPulmonary Artery StructureDrug TargetingPromoterPulmonary Arterial HypertensionQuality Of LifeDisease ProgressionHypoxiaNovel TherapeuticsPharmaceutical PreparationsDrug Candidate
Grant awards (6)
Development of a novel disease modifying oral therapy for pulmonary arterial hypertension.$1,276,514
R44 · FY2025 · HL · contact PI
Development of a novel disease modifying oral therapy for pulmonary arterial hypertension.$1,077,584
R44 · FY2024 · HL · contact PI
Preclinical Development of a Novel Disease Modifying Therapy for Pulmonary Arterial Hypertension$400,526
R33 · FY2021 · HL · contact PI
Preclinical Development of a Novel Disease Modifying Therapy for Pulmonary Arterial Hypertension$431,227
R33 · FY2020 · HL · contact PI
A Potential DDAH-Biotherapeutic to Preserve Kidney Function in Cardiac Surgery Patients$234,583
R43 · FY2020 · DK · contact PI
A Novel Disease Modifying Therapy for Progression of Pulmonary Arterial Hypertension$217,901
R43 · FY2019 · HL · contact PI